Home > Oncology > ESMO 2020 > Breast Cancer > Neoadjuvant treatment in patients with high-risk early breast cancer

Neoadjuvant treatment in patients with high-risk early breast cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
Both GeparOcto and IMpassion031 evaluated neoadjuvant treatment in patients with high-risk early breast cancer [1-3]. Atezolizumab significantly improved pathologic complete response (pCR) rates. GeparOcto randomised 961 patients with high-risk early breast cancer (TNBC, HER2-positive, or ER-positive/HER2-negative) to receive either 9 cycles of sequential neoadjuvant treatment with intense dose-dense epirubicin, paclitaxel, cyclophosphamide (iddEPC) or weekly treatment with paclitaxel plus non-pegylated liposomal doxorubicin for 18 weeks (PM). Patients with TNBC in the PM arm also received weekly carboplatin (Cb); in both treatment arms patients with HER2-positive disease received trastuzumab/pertuzumab. The primary endpoint, pathological complete response (pCR), did not differ between both arms in the whole cohort as well as in subgroups [1]. After a median follow-up of 47 months, there were no overall differences in invasive disease-free survival...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on